Trial Profile

Protocol I4V-MC-JAHN: A Phase 3 Multicenter, Double-Blind Study to Evaluate the Long-Term Safety and Efficacy of Baricitinib in Adult Patients with Atopic Dermatitis

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 06 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Baricitinib (Primary)
Indications Atopic dermatitis
Focus Registrational; Therapeutic Use
Acronyms BREEZE-AD3
Sponsors Eli Lilly and Company; Eli Lilly and Company (India) Pvt. Ltd; Eli Lilly Japan

12 Mar 2024 Results from substudy investigating the effects of dose downtitration in patients with AD who had achieved clear or almost clear skin after treatment with baricitinib 4-mg once daily, presented at the American Academy of Dermatology annual Meeting 2024
16 Jul 2023 This trial has been completed in Germany (End date: 12 Jul, 2023), according to European Clinical Trials Database record.
14 Jul 2023 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com